Free Trial

Scholar Rock Q3 2023 Earnings Report

Scholar Rock logo
$30.05 -2.10 (-6.53%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scholar Rock EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.53
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.55

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q3 2023
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Remove Ads

Scholar Rock Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
TD Cowen Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Scholar Rock announces Phase 3 SAPPHIRE data
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat